ACOG on Nasdaq
Alpha Cognition Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with TScan Therapeutics, Inc., Taysha Gene Therapies, Inc. or CURIS INC, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product Net brought in 63% of the revenue Alpha Cognition Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2025 |
|---|---|
| Product Net | $6.8M |
| License | $3.4M |
| Licensing | $598.4K |
Regions
United States brought in 66% of the revenue Alpha Cognition Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2025 |
|---|---|
| United States | $6.8M |
| [Canada] | $3.4M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue2¢$603.4K
- Research and development6¢$1.9M
- Selling, general and admin92¢$29.1M
Out of $10.2M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $10.2M | |
| Cost of product sales, excluding amortization of intangible asset | $474.0K | |
| Cost of licensing revenue | $1.4M | |
| Amortization of intangible asset | $21.5K | $79.9K |
| Research and development | $1.9M | $3.9M |
| Selling, general and administrative expenses | $29.1M | $8.0M |
| Total operating expenses | $32.9M | $12.0M |
| Loss from operations | -$22.7M | -$12.0M |
| Interest income | $1.9M | $161.7K |
| Grant income | $81.1K | $463.9K |
| Gain (loss) on derivative liabilities and conversion of convertible debt | $88.2K | -$3.2M |
| Other expenses | -$77.8K | -$237.0K |
| Total other income (expenses) | $2.0M | -$2.8M |
| Net loss and comprehensive loss | -$20.7M | -$14.8M |
| Weighted average stock outstanding, basic (in Shares) | 17.7M shares | 7.2M shares |
| Net loss per share, basic (in Dollars per share) | -$1.17 | -$2.04 |
| Adjusted net loss, diluted | -$20.8M | -$14.8M |
| Weighted average stock outstanding, diluted (in Shares) | 17.7M shares | 7.2M shares |
| Net loss per share, diluted (in Dollars per share) | -$1.18 | -$2.04 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $66.0M | $48.5M | |
| Restricted cash | $58.4K | $17.9K | |
| Accounts receivable, net | $4.2M | ||
| Inventory | $5.1M | $615.1K | |
| Prepaid expenses and other current assets | $3.5M | $1.1M | |
| Total current assets | $79.0M | $50.3M | |
| Other assets | $45.7K | ||
| Equipment, net | $328.5K | $27.1K | |
| Intangible assets, net | $391.4K | $413.0K | |
| Total assets | $79.7M | $50.7M | |
| Accounts payable and accrued liabilities | $9.0M | $2.4M | |
| Current deferred income | $153.2K | ||
| Total current liabilities | $9.1M | $3.4M | |
| Deferred income | $35.9K | ||
| Option liabilities | $3.2M | $2.4M | |
| Warrant liabilities | $4.8M | $5.8M | |
| Other long-term liabilities | $47.2K | $102.8K | |
| Total liabilities | $17.2M | $11.6M | |
| Common stock, no par value, unlimited stock authorized, 21,742,104 and 16,019,787 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | $133.9M | $99.1M | |
| Class B preferred stock, no par value, unlimited stock authorized, 316,655 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | $62 | $62 | |
| Additional paid-in capital | $25.8M | $16.5M | |
| Accumulated other comprehensive loss | -$104.3K | -$104.3K | |
| Accumulated deficit | -$97.1M | -$76.4M | |
| Total stockholders equity | $62.5M | $39.1M | -$4.7M |
| Total liabilities and stockholders equity | $79.7M | $50.7M | |
| Common stock, shares issued (in Shares) | 21.7M shares | 16.0M shares | |
| Common stock, shares outstanding (in Shares) | 21.7M shares | 16.0M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$20.7M | -$14.8M |
| Depreciation and amortization | $58.6K | $81.2K |
| Accrued expenditures for government grant | $53.1K | -$17.5K |
| Accrued interest | $66.0K | |
| Accrued interest income, related party | $2.5K | |
| Loss (gain) on derivative liabilities and conversion of convertible debt | -$88.2K | $3.2M |
| Change in fair value of bonus rights liability | -$55.6K | $18.7K |
| Non-cash debt issuance costs | $459.4K | |
| Provision for loan losses | $55.0K | |
| Impairment of intangible assets | $39.2K | |
| Loss on disposal of equipment | $18.0K | |
| Stock-based compensation | $4.9M | $1.1M |
| Shares issued for services | $2.3M | |
| Accounts receivable, net | -$4.2M | |
| Inventories | -$4.5M | -$615.1K |
| Prepaid expenses and other current assets | -$2.5M | -$671.7K |
| Accounts payable and accrued liabilities | $6.5M | $1.0M |
| Deferred income | $95.5K | |
| Net cash used in operating activities | -$20.4M | -$7.8M |
| Acquisition of equipment | -$293.5K | -$26.7K |
| Net cash used in investing activities | -$293.5K | -$26.7K |
| Units issued for cash | $3.7M | |
| Stock issued for cash | $34.3M | $52.8M |
| Stock issuance costs | -$2.5M | -$5.7M |
| Warrants issued for cash | $5.9M | |
| Exercise of options | $364.6K | $1.8K |
| Exercise of warrants | $1.0M | $300.0K |
| Repayment of promissory notes | -$911.5K | -$300.0K |
| Proceeds received from restricted government grant | $174.7K | $373.8K |
| Amounts paid from restricted government grant funds | -$134.1K | -$446.4K |
| Proceeds from the issuance of convertible debentures | $4.5M | |
| Debt issuance costs | -$459.4K | |
| Net cash provided by financing activities | $38.2M | $54.9M |
| Change in cash, cash equivalents, and restricted cash during the year | $17.5M | $47.1M |
| Cash paid for interest | $4.9K | $37.8K |
| Reallocation of fair value of share options upon exercise | $410.6K | $126.8K |
| Reclassification of derivative liability of warrants exercised | $903.2K | |
| Reclassification of derivative liability for warrants re-priced from CAD to USD exercise price | $4.3M | |
| Recognition of Option liabilities | $2.1M | |
| Common shares issued for share issuance costs | $928.9K | |
| Warrants issued for share issuance costs | $3.1M | |
| Common shares issued for services | $2.3M |
Former names
- Neurodyn Cognition Inc.Oct 16, 2015 to Oct 9, 20192
Recent filings
- Oct 2, 20264
- Sep 28, 20264
- Sep 23, 2026SCHEDULE 13G
- Sep 16, 20264
- Aug 24, 20264
- Aug 13, 202610-Q QUARTERLY REPORT
- Aug 4, 20264
- Jul 28, 20264
- Jul 24, 2026SCHEDULE 13G/A
- Jul 24, 20264
- Jun 29, 2026SCHEDULE 13G/A
- Jun 29, 20264
- Jun 23, 20268-K CURRENT REPORT
- Jun 15, 20264
- Jun 11, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6